ArticleAACE endocrinology and diabetes
Giant Prolactinoma: Challenges in Management.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Prolactinomas are the most common form of pituitary adenomas, 90% of which are microprolactinomas measuring <1 cm. A giant prolactinoma is defined as a prolactinoma measuring >4 cm with a serum prolactin level of >1000 ng/mL. We report a case of giant prolactinoma causing optic nerve compression that initially responded well to cabergoline and later developed intratumoral hemorrhage requiring transsphenoidal resection. Case Report: A 47-year-old man presented with blurry vision and intermittent headaches for 6 months. Visual field (VF) testing demonstrated bitemporal VF defect, which prompted magnetic resonance imaging of brain that showed a 4.1 × 3.1 × 3.1-cm pituitary macroadenoma with suprasellar extension compressing the optic chiasm. Laboratory evaluation revealed an increased prolactin level, low testosterone level, inappropriately normal luteinizing hormone level, and follicle-stimulating hormone level consistent with central hypogonadism. Cabergoline 0.5 mg twice weekly was started. Repeat VF testing and prolactin level in 4 weeks after starting cabergoline showed improvement. Nine months later, his symptoms worsened, and repeat magnetic resonance imaging showed intratumoral hemorrhage and that the size of the tumor had increased. He underwent an emergent transsphenoidal resection. After surgery, he developed central adrenal insufficiency and central hypothyroidism requiring steroid and thyroid hormone replacement. Discussion: Only a few cases of giant prolactinomas have been reported, and no clear guidelines for management of giant prolactinomas have been established. First-line medical management includes dopamine agonists such as cabergoline and bromocriptine. Conclusion: The dilemma between medical management and surgical management occurs during initial presentation of giant prolactinoma with VF defect. Our case report highlights the challenges and complications encountered in the treatment of a patient with giant prolactinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.